The frequency and availability of population-specific patient reported outcome measures and minimal clinically important differences among approved drugs in Canada.

PROMs and MCIDs referenced in CDR-CRR show similar trends. The majority are validated, but not necessarily in the study population of interest. Continued critical examination is required to evaluate new drugs specific to the population of interest.